Novartis' AveXis Highlights Interim Data From Phase 3 STRIVE Trial Of Zolgensma In Spinal Muscular Atrophy Type-1 'showed prolonged event-free survival, an early and rapid increase in CHOP-INTEND scores and significant milestone achievement'